VEA
STRO icon

Virtus ETF Advisers’s Sutro Biopharma STRO Stock Holding History

Virtus ETF Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,067
Closed -$88K – 471
2022
Q1 		$88K Sell
1,067
-64
-6% -$6.09K 0.04% 321
2021
Q4 		$168K Buy
1,131
+24
+2% +$4.3K 0.06% 297
2021
Q3 		$209K Sell
1,107
-57
-5% -$10.8K 0.09% 261
2021
Q2 		$216K Sell
1,164
-217
-16% -$42.5K 0.09% 286
2021
Q1 		$314K Buy
1,381
+23
+2% +$5.46K 0.13% 235
2020
Q4 		$295K Buy
+1,358
New +$225K 0.12% 220

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Virtus ETF Advisers's STRO Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Sutro Biopharma (STRO) in Q2 2022, closing a stake of 1,067 shares — an estimated $88K sold.

Virtus ETF Advisers first reported a position in STRO in Q4 2020 and held it in 6 quarters. The position peaked at $314K in Q1 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q2 2022.

  • Virtus ETF Advisers reported no remaining Sutro Biopharma position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,067 Sutro Biopharma shares in Q2 2022, an estimated $88K.
  • Virtus ETF Advisers first reported a position in Sutro Biopharma in Q4 2020 and held it in 6 quarters.
  • Virtus ETF Advisers's Sutro Biopharma position peaked at $314K in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.